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CI = confidence interval; EPRT = estrogen–progestin replacement therapy; ERT = estrogen replacement therapy; HRT = hormone replacement
therapy; RR = relative risk.
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Introduction
Menopausal hormone replacement therapy (HRT), most
commonly including estrogens alone or in combination
with progestins, is used to alleviate menopausal symptoms
and to prevent osteoporosis. Progestins are prescribed to
offset the increased risk for endometrial cancer associated
with estrogen replacement therapy (ERT). In the USA, it
has become increasingly common to prescribe estrogens
in combination with progestins since the early 1980s. An
estimated 45% of menopausal US women aged
25–74 years in the early 1970s reported ever using HRT.
Of those reporting HRT use in 1992, 31% reported taking
progestins [1]. Use of progestins began earlier in Scandi-
navian countries than in the USA [2].
Assessing breast cancer risk associated with HRT is com-
plicated by the fact that many different hormones, regi-
mens, and routes of administration have been used.
During the 1980s the most common type of estrogen–
progestin replacement therapy (EPRT) in the USA con-
sisted of estrogens administered for the first 21–25 days
of the calendar month and progestins added cyclically
during the last 10–14 days of estrogen treatment. Other
regimens, including continuous daily treatment with both
estrogens and progestins, were developed to avoid the
withdrawal bleeding that many women experience with
cyclic therapy [3]. More recently, new regimens were
introduced to prevent or minimize the breakthrough bleed-
ing that is common during the first months of combined/
continuous EPRT. These include the use of progestins
only every second or third month [4] or a continuous
estrogen/intermittent progestin regimen (3 days on,
3 days off) [3]. In addition, other formulations are undergo-
ing clinical trials or awaiting approval in the USA [3]. The
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most commonly used progestins in EPRT are the synthetic
progestins, which can be divided into those structurally
related to progesterone, which are most commonly used
in the USA [5,6], and those that are structurally related to
testosterone, which are frequently used in Europe and
Scandinavia [7,8].
Progestins and breast cell proliferation
Hormones are hypothesized to increase cancer risk by
increasing cell division, thereby increasing the risk for
genetic errors of various kinds or fixing an initial mutagenic
event. The vast majority of in vitro studies of normal breast
cells in culture and breast cancer cell lines have shown
that estrogens enhance breast cell proliferation, and that
the addition of progestins reduces this effect [9]. In con-
trast, in vivo studies of the mitogenic effects of estrogens
and progesterone on human breast epithelial cells in pre-
menopausal women, which show a predominance of pro-
liferative events during the luteal phase of the menstrual
cycle when levels of both estrogens and progesterone are
high, suggest that EPRT might have a more adverse effect
on breast cancer risk than ERT [10]. Studies of epithelial
cell proliferation in the normal postmenopausal breast in
relationship to different regimens of HRT, however, have
yielded discrepant results.
In a trial in which 40 postmenopausal women were randomly
assigned to one of four treatment groups (daily topical appli-
cation of a gel containing a placebo, estradiol, progesterone,
or a combination of estradiol and progesterone during the
14 days preceding breast surgery) [11], progesterone
reduced the estradiol-induced proliferation of breast epithe-
lial cells. It is notable, however, that the drug regimens used
in that study are not those typically used for HRT.
An observational study was conducted in which samples
of breast tissue containing normal epithelium from 185
postmenopausal patients undergoing surgery for benign
or malignant disease were stained for progesterone
receptor and Ki67 expression [12]. There was no associa-
tion between either estrogen or estrogen combined cycli-
cally with progestin and breast epithelial cell proliferation.
For patients on EPRT, information was not available
regarding the cycle of treatment at the time of surgery.
In a second observational study of 86 postmenopausal
women, combined/continuous EPRT was associated with
greater epithelial cell proliferation and breast epithelial cell
density than ERT or no HRT [13]. Moreover, the cell prolif-
eration associated with EPRT was localized to the terminal
duct lobular unit, where most breast cancers develop.
It is notable that estrogen plus progesterone has induced
more pronounced proliferative responses than estrogens
alone in the normal postmenopasual mammary gland in
some murine models and macaques [9,14].
Hormone replacement therapy and breast
cancer risk
Individual observational epidemiologic studies of HRT and
breast cancer risk have yielded conflicting results. For
instance, in a large prospective study [15], breast cancer
risk was significantly increased among women who were
currently using estrogen alone (relative risk [RR] 1.2, 95%
confidence interval [CI] 1.1–1.5) or estrogen plus progestin
(RR 1.4, 95% CI 1.2–1.7) as compared with post-
menopausal women who had never used hormones. In a
large case–control study [16], on the other hand, there was
no increase in breast cancer risk associated with use of
either estrogen alone or estrogen plus progestin. Such dis-
crepancies may reflect the relatively small number of users
of different types of hormone regimens even in the largest
studies, as well as the relatively low levels of risk involved.
In a collaborative reanalysis of 90% of the world’s epi-
demiologic data on HRT and breast cancer risk, which
included data from 51 epidemiologic studies, increases in
risk associated with HRT (without regard to type of
hormone or regimen) were limited to current or recent
users (those who stopped use 1–4 years previously) [17].
Among those women, the RR for each year of use was
1.023 (95% CI 1.011–1.036); the RR was 1.35 (95% CI
1.21–1.49) among women who used HRT for 5 or more
years relative to never users. The increase in risk was
greater among women with lower than among those with
higher weight and body mass index, and cancers diag-
nosed in HRT users were less advanced clinically than
those diagnosed in never users. Among the 39% of
hormone users for whom information on type of prepara-
tion was available, 80% had primarily used preparations
containing estrogen alone and 12% had used prepara-
tions containing both estrogen and progestin. The RR
associated with 5 or more years of recent use of estrogen
alone relative to never users was 1.34 (standard error
0.09), whereas the corresponding RR associated with use
of estrogen and progestin or progestin alone was 1.53
(standard error 0.33). Analyses were not done according
to type or regimen of progestin.
A number of subsequent observational epidemiologic
studies have reported on breast cancer risk associated
with EPRT as compared with ERT. Two of those studies
[8,18] found similar increases in breast cancer risk associ-
ated with EPRT and ERT, although in the latter of the
studies duration of EPRT use was shorter than duration of
ERT use. Other studies [5–7,19–22] have suggested
greater increases in risk with EPRT than with ERT. Among
participants in the Nurses’ Health Study [19], women with
natural menopause who used ERT had a 7.7% (95% CI
5.0–10.5) increase in risk per year of use, whereas those
who used estrogen plus progestin had a 13% (95% CI
7.2–19.1) increase in risk per year of use. The P value
associated with the comparison of the rate of increase246
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with estrogen plus progestin versus estrogen alone was
0.06. In the Breast Cancer Detection Demonstration
Project Follow-up Study [5], estrogen only and estro-
gen–progestin only were associated with 1% (95% CI
0.2–3) and 8.0% (95% CI 2–16) increases in risk per
year of use, respectively, among users during the previous
four years. The P value associated with the test of homo-
geneity of these estimates was 0.02. In a large
case–control study [6], ERT was associated with a 6%
(95% CI 0.97–15) increase in the RR for breast cancer
for each 5 years of use, whereas EPRT was associated
with a 24% (95% CI 7–45) increase. In another large
case–control study [20], ERT and EPRT were associated
with 2% (95% CI 1–3) and 4% (95% CI 1–8) increases
in the RR per year of use, respectively. Progestin only use
has been associated with a statistically significant
increase in risk in two studies [8,20]. Several studies have
suggested that EPRT is associated with greater increases
in risk in leaner than heavier women [5,8], which is consis-
tent with the collaborative reanalysis of the world’s data
[17]. Other studies have reported similar increases in risk
in lean and heavy women [20,23]. Increases in risk have
been noted for both testosterone-derived progestins [7,8]
and progesterone-derived progestins [5–6,18–20,22].
Several observational epidemiologic studies have exam-
ined the association between EPRT and selected tumor
characteristics. One noted an increase in risk only for
lobular carcinomas [22], whereas several others reported
greater increases in risk for lobular than ductal tumors
[18,20]. Other studies, however, reported increases in risk
with the vast majority of breast cancers with a ductal his-
tology [5] or for both ductal and lobular carcinomas [23].
In two studies that examined risk according to the
hormone receptor status of the tumors [18,23], increases
in risk were evident for hormone receptor positive tumors
but not for receptor negative tumors. One study [6] found
similar increases in risk across all stages of disease with
EPRT, whereas increases in risk associated with ERT
were limited to in situ disease. Another study [20] found
similar increases in risk for both localized and more
advanced breast cancer.
Several observational epidemiologic studies have
assessed breast cancer risk according to type of EPRT
regimen. One study [8] reported greater increases in risk
for the combined/continuous regimen than for the cyclic
regimen (19%/year versus 3%/year). Other studies
[18,20] reported similar increases in risk associated with
the cyclic and combined/continuous regimens. Yet
another study [6] found greater increases in risk with the
cyclic than with the combined/continuous regimen (odds
ratios per 5 years of use were 1.38 [95% CI 1.13–1.68]
and 1.09 [95% CI 0.88–1.35], respectively), but this dif-
ference was not statistically significant. In a study con-
ducted in Finland [4], where long cycle EPRT (adding a
progestin period every second or third month) has been
used since 1990, both the long cycle and monthly cycle
EPRT regimens were associated with statistically signifi-
cant 30% increases in breast cancer risk. Risk was not
evaluated as a function of dose or duration of use.
Results from two randomized controlled trials showed an
increase in breast cancer risk associated with the com-
bined/continuous estrogen–progestin regimen (0.625 mg
conjugated equine estrogen plus 2.5 mg medroxyproges-
terone acetate) [24,25]. The estrogen–progestin compo-
nent of the Women’s Health Initiative was stopped early,
in part because of an increased risk of breast cancer in
those taking estrogen plus progestin as compared with
placebo (hazard ratio 1.26, 95% CI 1.00–1.59) [24]. A
total of eight additional invasive breast cancers per
10,000 person-years were attributed to the estrogen–
progestin regimen. Those findings are consistent with the
relative hazard of 1.27 (95% CI 0.84–1.94) found after
6.8 years of follow-up in the Heart and Estrogen/Progestin
Replacement Study Follow-up [25], a randomized trial in
postmenopausal women with coronary disease.
Although HRT is associated with an increased incidence
of breast cancer, it has been associated with lower mortal-
ity from breast cancer in most studies that examined
breast cancer death among healthy hormone users as
compared with nonusers, possibly reflecting more favor-
able tumor characteristics associated with HRT use [26].
Published data are insufficient to assess associations
between the estrogen–progestin regimen, specifically,
and breast cancer mortality.
Hormone replacement therapy and
mammographic densities
Extensive areas of mammographic density, representing
stromal or epithelial tissue, have been associated with
substantially increased breast cancer risk. Although
changes in mammographic density have not been exam-
ined in relationship to changes in breast cancer risk,
changes in densities resulting from a variety of interven-
tions suggest that mammographic densities may be a
short-term marker of risk [27].
Most studies that examined changes in mammographic
density according to type of HRT regimen have found that
a greater percentage of women on EPRT than on ERT
experienced increases in density [28–32]. In one of those
studies [28], a double-blind randomized placebo-con-
trolled trial, the percentages of women who experienced
increases in density were similar among those taking
cyclic and combined/continuous EPRT: 23.5% in those
on the cyclic regimen with 10 mg medroxyprogesterone
acetate; 19.4% in those on the combined/continuous
estrogen–progestin with 2.5 mg medroxyprogesterone
acetate; 16.4% in those on the cyclic regimen with247
micronized progesterone; 3.5% in those taking estrogens
alone; and 0% in the placebo group. In a Swedish study of
changes in mammographic density assessed at two
screening examinations [29], a greater percentage of
women on combined/continuous EPRT than on cyclic
EPRT experienced increases in mammographic density
(28% and 10%, respectively), although both groups expe-
rienced greater increases in density than those on ERT
(5%). Other studies [30–32] reported that greater per-
centages of women on combined/continuous, but not
cyclic, EPRT exhibited increases in mammographic
density as compared with women on ERT. For instance, in
a study of 175 women participating in a population-based
screening program [32], increases in mammographic
density were observed in 52% of women receiving com-
bined/continuous EPRT, in 13% of those receiving the
cyclic regimen, and in 18% of those receiving ERT.
Conclusion
Taken together, these data suggest that the addition of
progestins to ERT does not counteract the adverse
effects of estrogens on the breast, as it does in the
endometrium. In fact, the data suggest that EPRT may
have a more adverse effect on risk for breast cancer than
does ERT. Many issues remain unresolved, however.
These include the effects of different regimens and doses
of EPRT, long duration use, and whether the effects vary
according to tumor characteristics, such as histology,
extent of disease, and hormone receptor status. Data from
several large studies that are currently underway may
provide answers to some of these questions [33].
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